A recent report found that the average wait time for the results for a COVID-19 test in July 2020 in the US is 4 days. This same report determined the mean and median waiting time 4.1 days and 3 days, respectively. Only 37% of people received test results within 2 days, and 21% waited more than 5 days. Such long response windows delay treatment determinations, obscure community spread and render contact tracing ineffective. The use case for an inexpensive, readily available SARS-CoV-2 assay is strong even if the assay's sensitivity is lower than current RT-PCR testing. Modeling suggests that providing decentralized, point-of-care testing with rapid feedback would have significantly greater impact on transmission vs. improving the absolute limit of detection of the assay. Such models incorporate the observation that infectious viral particles have not been recovered below approximately 100 copies/mL. Rapid antigen tests are starting to be deployed commercially. However, few antigen tests for SARS-CoV-2 have been authorized by regulatory authorities worldwide. As of July 19 th , 2020, only two such products have received emergency use authorization (EUA) from the US Food and Drug Administration. These two FDA EUA antigen assays are expensive, require instrumentation, and are currently available only to health care professionals. Efforts are underway to develop readily manufacturable antigen-based rapid diagnostic tests which do not rely on, or at most minimally rely on, access to instrumentation to meet an increasing global demand. In this paper we describe an LFA for the detection of SARS-CoV-2 nucleocapsid protein. We combined the results of our previously reported high-throughput robotic antibody screening efforts with our experience building a half-strip LFA for SARS-CoV-2 in order to develop a complete LFA that utilizes anterior nares swabs. If supply or cost constraints limit the availably of our selected antibody pair, our antibody screening efforts may be utilized to guide the selection of alternates. We report our LOD against irradiated virus in pooled nasal matrix. Clinical evaluation of this device is on-going. All materials and reagents utilized in this LFA were chosen from commercially available sources to support development of an "open source" COVID-19 antigen LFA.